Background-Mild elevations of cardiac troponin frequently occur after percutaneous coronary intervention (PCI), and patients with elevated post-PCI biomarkers have a worse prognosis. We used optical coherence tomography (OCT) to study the relationship between pre-PCI plaque morphology and post-PCI cardiac troponin I elevations. Methods and Results-One hundred thirty-one patients with normal pre-PCI cardiac troponin I levels underwent OCT before nonemergency stent implantation. Clinical and OCT findings were compared between patients with (nϭ31, 23.7%) and without (nϭ100, 76.3%) post-PCI cardiac troponin I of Ͼ3ϫupper reference limit (post-PCI myocardial infarction [MI]). After PCI, long-term follow-up data were collected. Post-PCI MI was associated with angiographic lesion length, type B2/C lesions, presence of thin-cap fibroatheroma, and fibrous cap thickness. In multivariable analysis, presence of thin-cap fibroatheroma (odds ratio, 10.47; 95% confidence interval, 3.74 to 29.28; PϽ0.001) and type B2/C lesions (odds ratio, 3.74; 95% confidence interval, 1.41 to 9.92; Pϭ0.008) were predictors of post-PCI MI. At a median follow-up of 12 months, cardiac event-free survival was significantly worse in patients with post-PCI MI (log-rank test 2 ϭ8.9; Pϭ0.003). Cox proportional hazards analysis showed that post-PCI MI (hazard ratio, 3.67; 95% confidence interval, 1.39 to 9.65; Pϭ0.009) and ejection fraction (hazard ratio, 0.96; 95% confidence interval, 0.92 to 0.99; Pϭ0.029) were independent predictors of adverse cardiovascular events during follow-up. Conclusions-Type B2/C lesions and the presence of OCT-defined thin-cap fibroatheroma can predict post-PCI MI in patients treated with elective stent implantation, who may require adjunctive therapy after otherwise successful PCI. (Circ Cardiovasc Interv. 2011;4:378-386.)
P ostprocedural cardiac biomarker elevations of creatine kinase-MB or troponin levels occur in 5% to 50% of patients undergoing percutaneous coronary intervention (PCI), depending on its definition, lesion and patient characteristics, and procedure-related factors. 1, 2 Multiple studies have shown a proportional relationship between the level of post-PCI cardiac biomarker elevation and the risk of adverse outcome, even among patients with an otherwise uncomplicated and successful PCI and after adjusting for other confounding factors. 3, 4 A recent study using contrastenhanced MRI showed that a post-PCI biomarker elevation is associated with new, irreversible myocardial injury on delayed-enhancement MRI. 5 The authors suggested that distal hyperenhancement represents new myocardial necrosis resulting from distal embolization of liberated particles during PCI, and the proximal type probably is due to side branch occlusion. Characteristic features of plaques, such as large plaque volumes and necrotic core areas, which are indicative of embolic events after PCI, have been reported in studies using integrated backscatter-intravascular ultrasound (IVUS) and virtual histology-IVUS. 6, 7 An optical coherence tomography (OCT)-derived lipid arc can predict no-reflow after PCI in patients with non-ST elevation-myocardial infarction (MI). 8 Few studies have shown a relationship between pre-PCI lesion subsets and post-PCI troponin levels in patients undergoing elective PCI. This issue has become of particular interest after the recent release of the universal definition of MI that states that a rise in cardiac troponin exceeding 3 times the 99th percentile of a normal reference population (upper reference limit, URL) should be labeled as PCI-related MI. 9 Intravascular OCT, a high-resolution imaging method for plaque characterization, 10 -12 provides information on the microstructures of atherosclerotic plaques, such as thin fibrous cap, lipid-rich plaque, and intracoronary thrombus, which may be responsible for plaque instability. 13 We hypothesized that OCT allows detection of characteristic features of plaque in patients undergoing nonemergency stenting and evaluation of lesion-related factors associated with post-PCI MI. To test this hypothesis, we investigated the relationship between OCT-derived morphological features of culprit plaques of patients with normal pre-PCI cardiac troponin I (cTnI) levels undergoing elective stenting and post-PCI MI. We also assessed whether post-PCI MI defined by the universal definition of MI affects long-term event-free survival in these patients.
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Methods
Study Population
From December 2008 to November 2009, a prospective, nonconsecutive series of 160 patients with an identifiable, de novo single culprit lesion in a native coronary artery, who underwent elective stenting at Tsuchiura Kyodo General Hospital, were eligible for the present study. Of the 160 patients, 132 had stable angina pectoris and 28 had unstable angina pectoris. All patients showed no cTnI elevation (Յ 0.30 ng/mL: institutional URL) both at admission and before PCI. Patients were excluded if they had significant left main disease, congestive heart failure, or renal insufficiency with a baseline serum creatinine level of Ͼ2.0 mg/dL (152 mol/L). In addition, patients with extremely tortuous vessels or heavy calcification and chronic total occlusion were excluded because of anticipated difficulty in advancing the OCT catheter. We also excluded patients treated with atheroablative, distal protection devices and aspiration thrombectomy. Thus, we initially performed OCT in 149 patients. (Figure 1 ). The angiographic criterion of Ͻ20% residual stenosis with Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow defined successful PCI. Patients with unsuccessful PCI and side branch occlusion (Ͼ1 mm; TIMI flow grade, 0 to 2) were excluded from analysis. Unstable angina pectoris was defined by a progressive crescendo pattern or angina at rest without increase in cTnI. Stable angina pectoris was defined as no change in frequency, duration, or intensity of anginal symptoms in the 6 weeks before intervention. The culprit lesion was identified on the basis of left ventricular wall motion abnormalities, ECG findings, angiographic lesion morphology, and scintigraphic defects. Platelet glycoprotein IIb/IIIa receptor inhibitors were not used because they are not available in Japan. The study protocol was approved by the institutional review board, and all patients provided written informed consent before PCI.
Biochemical Analysis
The Abbott Architect Troponin I assay (Abbott Diagnostics, Abbott Park, IL) was performed (limit of detection, 0.01 ng/mL; coefficient of variation Ͻ10% of at 0.032 ng/mL). At our institution, the URL was 0.3 ng/mL, which represents the 99th percentile of distribution of a reference control group. Biochemical measurements were performed at admission, before PCI, within 1 hour of PCI completion, 6 and 20 hours after PCI, and thereafter if the parameters were still increasing. The maximum value was considered to represent the presence or absence of post-PCI biomarker elevation. PCI-related MI was defined as a cTnI level of Ͼ0.90 ng/mL.
Angiographic Analysis
Quantitative coronary angiography analysis was performed with the use of a CMS-MEDIS system (Medis Medical Imaging Systems, Leiden, The Netherlands). The minimum lumen diameter, reference diameter, and lesion length were measured in diastolic frames from orthogonal projections. Coronary flow was assessed according to TIMI flow grade 14 and corrected TIMI frame count. 15 The culprit lesion was determined by using coronary angiograms and corrobo-rated with information from the patient's ECG, nuclear or echocardiographic stress test, and left ventriculogram.
PCI Procedure
All patients received aspirin (200 mg/d) and clopidogrel (75 mg/d, 300 mg loading dose) at least 24 hours before PCI. All patients received an intravenous bolus injection of 10 000 IU heparin and intracoronary isosorbide dinitrate (2 mg) before angiography, and an additional bolus of 2000 IU was given every hour if the procedure lasted for more than 1 hour. PCI procedures were performed using a 6F guiding catheter through the radial approach. The type of stent was selected at the operator's discretion. All patients underwent coronary stent implantation with predilatation. To avoid aggressive stent expansion, stent size was determined by using on-line quantitative coronary angiography and IVUS. After achieving the angiographic end point, IVUS examination was performed to confirm optimal stent deployment, and additional PCI was performed in the case of suboptimal results.
OCT Image Acquisition and Analysis
OCT image acquisition was performed with the use of M3-CV and Image Wire 2 catheters (Lightlab Imaging, Westford, MA). This system provides an axial resolution of 10 to 15 m and lateral resolution of 20 to 40 m. After control angiograms were obtained, the imaging wire was positioned distal to the region of interest with an occlusion balloon catheter (Helios; Goodman Co Ltd, Nagoya, Japan) located proximal to the lesion. To clear the blood, the occlusion balloon was inflated to 0.5 atm, and lactated Ringer solution was continuously infused (0.5 mL/s) into the coronary artery through the distal chip of the occlusion catheter. The entire length of the lesion was imaged with an automated pullback system at 1 mm/s. When a lesion was located close (Ͻ1 cm) to the ostium of the coronary arteries, we used the continuous-flushing nonocclusive technique for OCT imaging. To eliminate blood from the vessel without occlusion, we infused commercially available dextran-40 (Low Molecular Dextran L, Otsuka Pharmaceutical Factory, Tokushima, Japan) and lactated Ringer solution directly from the guiding catheter at a rate of 3.0 to 4.0 mL/s, using a power injector (Angimat Illumena, Liebel-Flarsheim, Cincinnati, OH). The image data were digitally stored for offline analysis. The image location of all target sites was determined by using fluoroscopic reference and landmarks, such as the aorto-ostial junction, proximal and distal side branches, and calcification sites, in combination with the constant pull-back speed of the imaging wire and OCT findings of each plaque. Offline analysis was performed with proprietary software (LightLab Imaging). The OCT data were analyzed by 2 independent investigators blinded to the angiographic and clinical findings, using previously validated criteria for OCT plaque characterization. 12, 13, 16 Any discordance between the 2 investigators was resolved by consensus reading. Contiguous cross sections were analyzed at 0.5-mm intervals. The lipid content of a plaque was semiquantified as the number of involved quadrants on cross-sectional images. For each plaque, the cross-sectional image with the highest number of lipid quadrants was used for further analysis. For all images with a lipid core, the overlying fibrous cap thickness was measured at its thinnest part. The average of 3 measurements was taken for each image. For each culprit plaque, the minimum value was used for subsequent analysis. When a plaque contained 2 or more lipidcontaining quadrants, it was considered a lipid-rich plaque, whereas a thin-cap fibroatheroma (TCFA) was defined as a lipid-rich plaque with a fibrous cap thickness of Ͻ70 m. The presence of fibrous cap disruption and intracoronary thrombi were also noted. Fibrous cap disruption was identified by the presence of fibrous cap discontinuity and cavity formation of the plaque, and a plaque with fibrous cap disruption was termed a ruptured plaque. In the ruptured plaque, residual fibrous cap was identified as a flap between the lumen and the cavity of the plaque, and its thickness was measured at the thinnest part. Intracoronary thrombi were identified by mass images protruding into the lumen. Interobserver and intraobserver differences were assessed by the evaluations of 2 observers and 1 observer, respectively, at 2 separate time points.
In-Hospital Clinical Outcome
In-hospital complications and outcome factors included potentially fatal arrhythmias (ventricular tachycardia, ventricular fibrillation, and advanced atrioventricular block), congestive heart failure (the presence of a third heart sound, Killip class Ն2, Forrester subset Ն2, or evidence of radiographic pulmonary congestion), disabling stroke, reinfarction, target vessel revascularization, cardiac surgery, length of hospital stay, and cardiac death.
Follow-Up
Follow-up data were collected at regular intervals in the outpatient clinic or through telephone interviews, by personal communication with the patient's physician, and by reviewing the patient's hospital records in the case of rehospitalization. Patients who underwent subsequent coronary revascularization were documented at the time of the new procedure. Adverse events included death, nonfatal MI, a new coronary revascularization procedure (coronary bypass surgery, repeat target lesion PCI, target vessel PCI for a new lesion, PCI for a new lesion in a nontarget vessel), or congestive heart failure requiring hospitalization. SPSS 14 .0 (SPSS Inc, Chicago, IL) was used for all analyses. Normality of the data was verified by the Kolmogorov-Smirnov test. Categorical data were expressed as absolute frequencies and percentages and compared by use of the 2 or Fisher exact test, as appropriate. Continuous variables were expressed as meanϮstandard deviation for normally distributed variables and as median (25th to 75th percentiles) for nonnormally distributed variables, and compared by use of the Student t test and Mann-Whitney U tests, respectively. To control for multiple comparison, pairwise tests of incidence were performed if the contingency table for all 3 variables was significant. Differences in fibrous cap thickness among groups were analyzed using a Kruskal-Wallis test. Post hoc comparisons after the Kruskal-Wallis test were performed using pairwise comparisons of subgroups using MedCalc (MedCalc Software, version 11.6, Mariakerke, Belgium). Interobserver and intraobserver variabilities of OCT findings were assessed by the statistic of concordance. The relationship between post-PCI MI (dependent variable), clinical and angiographic characteristics, OCT findings, and other potential confounders were assessed using multivariable logistic regression analysis (stepwise forward method) to determine whether OCT findings remained associated with post-PCI MI. Associated variables on univariable analyses (PϽ0.05) were included in the model. Considering the associations among factors obtained from OCT findings, the presence of TCFA was included as an OCT-derived factor in multivariable analysis. At follow-up data analysis, differences in combined adverse events between patients with or without post-PCI MI were analyzed with the Kaplan-Meier method. Event-free survival curves were compared using the Mantel-Cox test. Simple Cox regression analyses for combined adverse events using the presence of post-PCI MI and other clinical and angiographic variables were performed to identify predictors of adverse events during in-hospital and follow-up periods. Hazard ratios with corresponding 95% confidence intervals are reported. All variables associated with adverse events at the PϽ0.05 level in univariable analysis were then tested in a multivariable Cox regression analysis. PϽ0.05 indicated statistically significant.
Statistical Analysis
Results
Occlusive dissection was successfully treated in 1 patient of 149 who underwent OCT examination. Two patients showed hemodynamic disturbance with ST-segment elevation caused by massive distal embolization, requiring an intra-aortic balloon pump, and 2 patients had distal embolization exhibiting final TIMI flow grade 2. Side-branch occlusion was detected in 9 patients, and stent delivery failed in 1. They were excluded from analysis. Two patients were additionally excluded because of insufficient OCT image quality. Thus, we evaluated 131 lesions of 131 patients (107 stable angina pectoris and 24 unstable angina pectoris) who were successfully treated with elective stenting (Figure 1 ).
Patient Characteristics and Angiographic and Procedural Results
The baseline characteristics and angiographic findings are summarized in Table 1 and Table 2 , respectively. Thirty-one patients (23.7%) showed post-PCI MI. There was no significant difference in baseline clinical characteristics between patients with post-PCI MI and those without. All 131 lesions were successfully treated with stent implantation: 42 lesions with sirolimuseluting stents, 59 with paclitaxel-eluting stents, 8 with zotarolimus-eluting stents, and 22 with bare-metal stents. Figure 2 shows representative pre-PCI OCT images. No serious complications were observed during OCT examination, and no patients presented with worsening of coronary flow or symptoms after OCT examination. The OCT findings are summarized in Table 3 . When patients were divided into tertiles by cap thickness, post-PCI MI was significantly more frequent and the peak cTnI value was significantly greater in the thinnest tertile of cap thickness (Figures 3 and 4 ).
OCT Findings
Predictors of Post-PCI MI
The results of univariable and the multivariable logistic regression analyses for post-PCI MI are given in Table 4 . In multivariable analysis, the presence of TCFA (odds ratio, 10.47; 95% confidence interval, 3.74 to 29.28; PϽ0.001) and type B2/C lesions (odds ratio, 3.74; 95% confidence interval, 1.41 to 9.92; Pϭ0.008) remained as predictors of post-PCI MI.
In-Hospital Course and Follow-Up
No patients were lost to follow-up in the present study, and there was no difference in the median follow-up period between patients with post-PCI MI and those without. There was no difference in the length of index hospital stay between the 2 groups with or without post-PCI MI. Early events (during 30-day follow-up) in patients with post-PCI MI included 2 events of congestive heart failure on days 1 and 19. One of them showed a transient slow coronary flow during PCI and required adjunctive therapy for congestive heart failure on day 1. Up to 100 days from the index PCI, there was no adverse event in the patients without post-PCI MI, whereas 4 adverse events were observed in the post-MI group, including 1 MI. During a median follow-up period of 12 months (7 to 18 months), 1 patient with post-PCI MI died. The cumulative rate of adverse cardiac events was 13.0% (17/131) ( Table 5 ). Events including target vessel revascularization, nonfatal MI, and unstable angina pectoris were related to the originally stented culprit lesion in 6 patients (66.6%) and to nonculprit lesions in 3 (33.3%). Event-free survival was significantly worse in patients with post-PCI MI than those without ( Figure 5 ).
When baseline clinical and instrumental findings in patients with and without adverse cardiac events during follow-up were compared, no significant differences were observed regarding risk factors, clinical characteristics, coronary anatomy, or procedural factors (balloon/artery ratio, balloon inflation time, stent length, and postdilatation pressure) except for ejection fraction at discharge and presence of post-PCI MI ( Table 6 ). All patients had high rates of optimal medical therapy during hospital stay, at discharge, and during follow-up, with no differences observed between the groups with and without adverse events. Stepwise multivariable Cox regression analysis showed that post-PCI MI and low ejection fraction remained independent predictors of adverse cardiac events during follow-up (Table 7) .
Intraobserver and Interobserver Variability
Intraobserver variability yielded high concordance for the presence of lipid-rich plaques (ϭ0.86), diagnosis of TCFA (ϭ0.82), thrombi (ϭ0.90), and plaque rupture (ϭ0.86). Interobserver variability showed slightly lower concordance for the presence of lipid-rich plaques (ϭ0.78), TCFA (ϭ0.80), thrombi (ϭ0.86), and plaque rupture (ϭ0.80). Mean interobserver difference for the thinnest cap thickness was 6.3Ϯ9.7 m; mean intraobserver differences were 4.8 m Ϯ6.7 m.
Discussion
The present study showed a significant relationship between OCT-derived pre-PCI plaque characteristics and procedure- related MI (Type 4a) defined by the universal definition of MI. 9 TCFA frequency was greater in patients who had post-PCI MI after elective stent implantation. Multivariable analysis demonstrated that post-PCI MI was predicted by the presence of TCFA at the culprit lesion and type B2/C lesions in patients treated with elective stenting. During long-term follow-up, patients with post-PCI MI showed a worse clinical course than those without. Several studies have linked cardiac marker elevations with increased mortality or recurrent MI, 3, 4, 17, 18 although inconsistent conclusions have been reported. Severe, acute complications are rare, but mild, asymptomatic release of biocardiac markers of myocardial necrosis is frequently observed after an otherwise technically successful coronary intervention. 1, 2, 18 Although the pathophysiology of post-PCI myocardial necrosis is multifactorial, embolization of debris or calcified plaque material, or exposure of thrombogenic material to the coronary flow, which may cause thrombus formation, appears to play a key role. 5, 19 Why procedural biomarker elevations influence long-term mortality remains to be determined. One potential mechanism may be related to myocardial damage during PCI, which leads to left ventricular dysfunction or electric instability. Alternatively, cardiovascular mortality and morbidity are highly dependent on the extent and severity of atherosclerosis or active atherosclerotic processes. 20 The presence of TCFA predicted cTnI elevations in the present study, suggesting that presence of TCFA correlates with more progressive atherosclerosis and results in distal embolization by liberated materials during PCI. Previous studies have shown a relationship between pre-PCI lesion subsets and post-PCI biomarker levels. Kotani et al 21 reported that distal embolization and no-reflow may be caused by gruel from an atheroma attributable to mechanical plaque disruption during PCI, suggesting that both thrombus and lesion plaque components may have an impact on myonecrosis. Uetani et al 6 used integrated backscatter-IVUS to show that large plaque volumes and lipid-rich plaques may be indicative of embolic events after stent implantation in patients with elective stenting, resulting in myocardial injury. Recently, using virtual histology-IVUS, Hong et al 7 showed that post-PCI troponin I elevation occurred in lesions with a large necrotic core area. The present study supports their findings that the presence of OCT-defined TCFA can predict post-PCI MI defined by the universal definition 9 in patients treated with elective stenting. Cheruvu et al 22 showed an inverse relationship between necrotic core size and cap thickness. Our finding that post-PCI MI is more likely to occur in lesions with a thinner fibrous cap is partially supported by their findings that the mean necrotic core size was greatest in ruptured plaques, followed by TCFA, and then by other fibroatheromas. This suggests that as the necrotic cores of TCFA enlarge, they are more likely to be destroyed by PCI, leading to cardiac marker elevation. The consequence of the relationship between thinner cap thickness and potential biomarker elevation might be that plaques that are most susceptible to disruption by PCI also contains the greatest amount of lipid-rich thrombogenic necrotic materials. The present study suggests that mechanical disruption of lipid-rich plaques, especially those containing TCFA that can easily be destroyed, may introduce outflow of thrombogenic components into the coronary flow and cause myocardial tissue-level microcirculation disturbances and distal embolization, resulting in post-PCI MI.
Our study excluded patients with elevated baseline cTnI values; therefore, our findings may be more pertinent to a lowto medium-risk population in the setting of elective PCI. However, biomarker elevation after PCI may highlight patients with more unstable plaques who are candidates for recurrent cardiovascular events. This hypothesis appears to be consistent with Ellis et al 17 : They identified an early high-risk period of events for patients with creatine kinase-MB elevation after PCI, in addition to a late mortality risk beyond 12 months. Biomarker elevation, especially a small or mild increase, may be a risk marker for disease burden or lesion complexity and not a causal mediator of late mortality. For treating high-risk lesions or patients with TCFA, drug administration or therapies before PCI, including glycoprotein IIb/IIIa inhibitors, statin, and dual antiplatelet therapy, should be considered. Distal or proximal protection devices might be effective in reducing distal embolization in these high-risk patients. There is little disagreement regarding the prognostic consequences of large periprocedural MIs, but the clinical significance of smaller enzymatic MIs in patients with otherwise successful PCI continues to be controversial. Continued refinement in PCI strategy, devices, and adjunct pharmacology is required to suppress periprocedural PCI-related myocardial damage and enhance the safety of coronary revascularization, especially in patients with TCFA. Figure 5 . Cumulative frequency of adverse events in patients with or without postpercutaneous coronary intervention (PCI) myocardial infarction. Cumulative probability of events were significantly different between the 2 groups (Mantel-Cox 2 ϭ8.9, Pϭ0.003). URL indicates upper reference limit; cTnI, cardiac troponin I. MI indicates myocardial infarction; PCI, percutaneous coronary intervention; UAP, unstable angina pectoris; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; WBC, white blood cell; LDL, low-density lipoprotein; HDL, high-density lipoprotein; URL, upper reference limit; MLD, minimal lumen diameter; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; and CTFC, corrected TIMI frame count. Ejection fraction, % 0.014 0.95 0.91-0.99 0.029 0.96 0.92-0.99 cTnI indicates cardiac troponin I; URL, upper reference limit; HR, hazard ratio; and CI, confidence interval.
